Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.
A pilot chemoprevention study from the Royal Marsden Hospital in the United Kingdom demonstrated that tamoxifen could be administered safely to healthy women. This led to the establishment of multicenter trials, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and Italian National Cancer Institute trials. An interim analysis of the Royal Marsden Hospital trial did not detect a preventive effect. The Italian trial concurred with the Royal Marsden Hospital trial. In contrast, the larger NSABP study detected a 49% reduction in the incidence of breast cancer with tamoxifen chemoprevention. Possible reasons for the different results are examined and the implications for tamoxifen chemoprevention are discussed.